Comparative Pharmacology
Head-to-head clinical analysis: LEVLITE versus N E E 1 35 21.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LEVLITE versus N E E 1 35 21.
LEVLITE vs N.E.E. 1/35 21
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Levonorgestrel is a progestin that suppresses ovulation by inhibiting gonadotropin release (LH and FSH) and alters cervical mucus, endometrial thickness, and tubal motility.
Combination estrogen-progestin contraceptive: ethinyl estradiol (estrogen) and norethindrone (progestin). Suppresses gonadotropin (FSH, LH) release via negative feedback, inhibiting ovulation; increases cervical mucus viscosity to impede sperm penetration; alters endometrial development to reduce implantation likelihood.
One tablet (levonorgestrel 0.1 mg, ethinyl estradiol 0.02 mg) orally once daily for 21 days, followed by 7 placebo tablets.
One tablet orally once daily for 21 days, followed by 7 days off.
None Documented
None Documented
Terminal elimination half-life: 21-28 hours; clinical context: permits once-daily dosing
Norethindrone: terminal half-life 7-8 hours; Ethinyl estradiol: terminal half-life 12-14 hours (with enterohepatic recycling). Clinically, steady state achieved after 5-7 days.
Renal: ~50% (30% as unchanged drug, 20% as metabolites); Fecal: ~40%; Biliary: minor
Norethindrone (NET) and ethinyl estradiol (EE) are excreted primarily in urine (~50-60% as metabolites) and feces (~30-40% as metabolites); less than 1% excreted unchanged.
Category C
Category C
Oral Contraceptive
Oral Contraceptive